{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:05:04Z","timestamp":1793135104520,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016396","name":"Association Fran\u00e7aise d'Urologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007175","name":"Conseil National de la Recherche Scientifique","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007175","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"National Institute of Health and Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018737","name":"Laboratory of excellence Inflamex","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006431","name":"Canc\u00e9rop\u00f4le Ile de France","doi-asserted-by":"publisher","award":["2022-1-EMERG-07-INSERM_7-1"],"award-info":[{"award-number":["2022-1-EMERG-07-INSERM_7-1"]}],"id":[{"id":"10.13039\/501100006431","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004097","name":"Fondation ARC pour la Recherche sur le Cancer","doi-asserted-by":"publisher","award":["ARCPGA12021 020003101_358 7"],"award-info":[{"award-number":["ARCPGA12021 020003101_358 7"]}],"id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.isci.2026.114676","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:15:57Z","timestamp":1768263357000},"page":"114676","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["BCG immunotherapy for bladder cancer triggers systemic and local BCG-specific CD4+ Th1 responses"],"prefix":"10.1016","volume":"29","author":[{"given":"Paul","family":"Rollin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Pluskwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Artru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Le Vaslot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Kartasheva-Ebertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Biron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaux","family":"Bossis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Onodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"LeMaoult","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Rouas-Freiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu F.","family":"Chevalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia S.","family":"Lindestam Arlehamn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Sette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Masson-Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Desgrandchamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1719-9736","authenticated-orcid":false,"given":"Pierre","family":"Tonnerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.114676_bib1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.isci.2026.114676_bib2","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S0022-5347(05)67282-5","article-title":"The challenge of improved diagnostic and prognostic indicators of superficial bladder cancer","volume":"164","author":"Lamm","year":"2000","journal-title":"J. Urol."},{"key":"10.1016\/j.isci.2026.114676_bib3","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.purol.2022.08.006","article-title":"French AFU Cancer Committee Guidelines - Update 2022-2024: Non-muscle-invasive bladder cancer (NMIBC)","volume":"32","author":"Neuzillet","year":"2022","journal-title":"Prog. Urol."},{"key":"10.1016\/j.isci.2026.114676_bib4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J. Urol."},{"key":"10.1016\/j.isci.2026.114676_bib5","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.isci.2026.114676_bib6","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","article-title":"Mechanisms of BCG immunotherapy and its outlook for bladder cancer","volume":"15","author":"Pettenati","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.isci.2026.114676_bib7","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/01.ju.0000073852.24341.4a","article-title":"Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer","volume":"170","author":"B\u00f6hle","year":"2003","journal-title":"J. Urol."},{"key":"10.1016\/j.isci.2026.114676_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF00941903","article-title":"Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer","volume":"25","author":"de Boer","year":"1997","journal-title":"Urol. Res."},{"key":"10.1016\/j.isci.2026.114676_bib9","first-page":"611","article-title":"Novel insights into the mechanism of action of intravesical immunomodulators","volume":"19","author":"Mitropoulos","year":"2005","journal-title":"In Vivo (Athens)"},{"key":"10.1016\/j.isci.2026.114676_bib10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00294021","article-title":"Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis","volume":"19","author":"de Boer","year":"1991","journal-title":"Urol. Res."},{"key":"10.1016\/j.isci.2026.114676_bib11","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0022-5347(17)35678-1","article-title":"T-cell subsets required for intravesical BCG immunotherapy for bladder cancer","volume":"150","author":"Ratliff","year":"1993","journal-title":"J. Urol."},{"key":"10.1016\/j.isci.2026.114676_bib12","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0022-5347(05)65469-9","article-title":"Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer","volume":"167","author":"Saint","year":"2002","journal-title":"J. Urol."},{"key":"10.1016\/j.isci.2026.114676_bib13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1043-4666(02)00490-8","article-title":"Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect","volume":"21","author":"Luo","year":"2003","journal-title":"Cytokine"},{"key":"10.1016\/j.isci.2026.114676_bib14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41564-019-0618-z","article-title":"Evolution of the innate and adaptive immune response in women with acute Zika virus infection","volume":"5","author":"Tonnerre","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.isci.2026.114676_bib15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2807\/esm.11.03.00604-en","article-title":"European survey of BCG vaccination policies and surveillance in children, 2005","volume":"11","author":"Infuso","year":"2006","journal-title":"Euro Surveill."},{"key":"10.1016\/j.isci.2026.114676_bib16","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.4049\/jimmunol.158.4.1949","article-title":"Human T cell responses induced by vaccination with Mycobacterium bovis bacillus Calmette-Gu\u00e9rin","volume":"158","author":"Ravn","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.isci.2026.114676_bib17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imr.12274","article-title":"T cells and adaptive immunity to Mycobacterium tuberculosis in humans","volume":"264","author":"Jasenosky","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.isci.2026.114676_bib18","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jprot.2012.09.010","article-title":"A comprehensive proteomic analysis of Mycobacterium bovis bacillus Calmette\u2013Gu\u00e9rin using high resolution Fourier transform mass spectrometry","volume":"77","author":"Zheng","year":"2012","journal-title":"J. Proteomics"},{"key":"10.1016\/j.isci.2026.114676_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069892","article-title":"Antigen-Specific CD4 T Cells Are Induced after Intravesical BCG-Instillation Therapy in Patients with Bladder Cancer and Show Similar Cytokine Profiles as in Active Tuberculosis","volume":"8","author":"Els\u00e4\u00dfer","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2026.114676_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.934","article-title":"The MegaPool Approach to Characterize Adaptive CD4+ and CD8+ T Cell Responses","volume":"3","author":"da Silva Antunes","year":"2023","journal-title":"Curr. Protoc."},{"key":"10.1016\/j.isci.2026.114676_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003586","article-title":"Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer","volume":"4","author":"Biot","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2026.114676_bib22","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1172\/JCI89717","article-title":"ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence","volume":"127","author":"Chevalier","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2026.114676_bib23","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.eururo.2018.06.045","article-title":"Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy","volume":"74","author":"Chevalier","year":"2018","journal-title":"Eur. Urol."},{"key":"10.1016\/j.isci.2026.114676_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008020","article-title":"Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential","volume":"11","author":"Derr\u00e9","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.114676_bib25","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20240045","article-title":"Urine scRNAseq reveals new insights into the bladder tumor immune microenvironment","volume":"221","author":"Tran","year":"2024","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.isci.2026.114676_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.970931","article-title":"CyTOF analysis identifies unusual immune cells in urine of BCG-treated bladder cancer patients","volume":"13","author":"Castellano","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.114676_bib27","doi-asserted-by":"crossref","first-page":"694","DOI":"10.4161\/onci.20526","article-title":"Detection of functional antigen-specific T cells from urine of non-muscle invasive bladder cancer patients","volume":"1","author":"Pieraerts","year":"2012","journal-title":"OncoImmunology"},{"key":"10.1016\/j.isci.2026.114676_bib28","doi-asserted-by":"crossref","first-page":"39916","DOI":"10.18632\/oncotarget.9537","article-title":"Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Gu\u00e9rin therapy in bladder cancer","volume":"7","author":"Pichler","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.isci.2026.114676_bib29","doi-asserted-by":"crossref","first-page":"18627","DOI":"10.1073\/pnas.2004421117","article-title":"Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-\u03b3 signaling","volume":"117","author":"Antonelli","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.114676_bib30","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.eururo.2022.09.008","article-title":"Elevated T-cell Exhaustion and Urinary Tumor DNA Levels Are Associated with Bacillus Calmette-Gu\u00e9rin Failure in Patients with Non-muscle-invasive Bladder Cancer","volume":"82","author":"Strandgaard","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.isci.2026.114676_bib31","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.euf.2021.06.001","article-title":"Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients","volume":"8","author":"Benmerzoug","year":"2022","journal-title":"Eur. Urol. Focus"},{"key":"10.1016\/j.isci.2026.114676_bib32","first-page":"TPS4589","article-title":"ALBAN: An open label, randomized, phase III trial, evaluating efficacy of atezolizumab in addition to one year BCG (bacillus Calmette-Guerin) bladder instillation in BCG-naive patients with high-risk nonmuscle invasive bladder cancer (AFU-GETUG 37)","volume":"37","author":"Roupret","year":"2019","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.isci.2026.114676_bib33","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2217\/fon-2023-0271","article-title":"CREST: phase III study of sasanlimab and Bacillus Calmette-Gu\u00e9rin for patients with Bacillus Calmette-Gu\u00e9rin-na\u00efve high-risk non-muscle-invasive bladder cancer","volume":"20","author":"Steinberg","year":"2024","journal-title":"Future Oncol."},{"key":"10.1016\/j.isci.2026.114676_bib34","first-page":"TPS500","article-title":"A phase III, randomized, open-label, multicenter, global study of durvalumab and bacillus calmette-gu\u00e9rin (BCG) versus BCG alone in high-risk, BCG-na\u00efve non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC)","volume":"37","author":"De Santis","year":"2019","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.isci.2026.114676_bib35","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial","volume":"31","author":"Shore","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.114676_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005760","article-title":"A Quantitative Analysis of Complexity of Human Pathogen-Specific CD4 T Cell Responses in Healthy M. tuberculosis Infected South Africans","volume":"12","author":"Lindestam Arlehamn","year":"2016","journal-title":"PLoS Pathog."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226000519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226000519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:41:48Z","timestamp":1791337308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226000519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2589004226000519"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.114676","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BCG immunotherapy for bladder cancer triggers systemic and local BCG-specific CD4+ Th1 responses","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.114676","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"114676"}}